New drug news: Key highlights from the FDA’s 2023 Annual Report

29 July 2024

By Dr Nicola Davies

The US Food and Drug Administration’s (FDA) Office of New Drugs (OND), part of the Center for Drug Evaluation and Research (CDER), plays a pivotal role in advancing public health by facilitating access to novel, effective and safe drugs that address unmet clinical needs.

The 2023 OND Annual Report showcases the organization’s commitment to going beyond merely approving new drugs to fostering innovation in drug design and development.1 Indeed, the office’s key achievements in 2023 include:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK